STOCKS TELEGRAPH

Tag: NASDAQ: TLSA

  • Tiziana Life Sciences Inc. (TLSA) stock rises in the current market trading. Why is it so?

    Tiziana Life Sciences Inc. (TLSA) stock surges by 9.06% in the current market trading session after TLSA stock announced the positive progress of the Foralumab program, which is designed to counter COVID-19 and secondary progressive multiple sclerosis. Tiziana Life Sciences plc is a dual-listed biotechnology firm specializing in the research and development of novel molecules to fight diseases like cancer, inflammation, and other infectious diseases in humans.

    What is happening?

    TLSA stock has declared that the US Food and Drug Administration (FDA) has approved the use of Foralumab, a completely human anti-CD3 monoclonal antibody, in a secondary progressive multiple sclerosis (SPMS) patient at Harvard University’s Brigham and Women’s Hospital (BWH), Boston, MA. This is the first time a nasally administered antibody will be provided to a patient with SPMS, and it will be handled under an Individual Patient Expanded Access IND. The treatment will begin in the second quarter of 2021 and will last for six months.

    To test microglial imaging, researchers at BWH will perform comprehensive routine protection, neurological, imaging, and PET studies on this patient. Normal investigations at the BWH will include the modification of immunological and neurodegenerative indicators.

    Previous record of Phase 1 Trial

    Tiziana previously completed a Phase 1 trial in healthy subjects with a single-site, double-blind, placebo-controlled, multiple ascending dose (MAD) one time in a day dosing for 5 days with nasally administered Foralumab. At doses up to 250 mg, the treatment was well received, with no drug-related adverse effects recorded. Professor Howard of BHW invented nasal foralumab.

    Also,

    TLSA had previously confirmed that the Clinical Trial of Nasal Administration with Foralumab in COVID-19 patients in Brazil had yielded promising results. Nasally administered Foralumab at 100 mg/day for a 10-day treatment period was found to be well-tolerated, with no serious adverse effects reported. Clinical evidence suggested that the procedure reduced lung inflammation significantly. This indicates that the recent development is expected to raise the progress graph for TLSA.

  • Stocks to Watch as Markets Look Set for a Calm, Boring Day

    Stocks to Watch as Markets Look Set for a Calm, Boring Day

    The markets are calm this morning, but they are largely positive. Investors are awaiting news from the ongoing Federal Reserve policy meeting. Part of the calm stems from the fact that the markets are not expecting much of a change from the Fed’s earlier stance on its inflation policy. Earlier, the Federal Reserve chairman Jerome Powell had stated that the Fed was implementing a new policy that it’s calling Average Inflation Targeting. Through this policy, the Federal Reserve is ready to allow prices to rise above the 2% target for some time, and use this to compensate for when inflation has to run below the targeted levels for extended periods. Since there are no expectations of a change from this stance from the current meeting, it has not created any kind of volatility in the markets. Nonetheless, the momentum is largely positive at the moment. The markets are still riding on the increased possibility of a COVID -19 vaccine coming out before the end of the year.  This would help drive up the economy to match the momentum that has been experienced in the equity markets over the last 5 months during the pandemic. Despite the relative calmness in the markets, there are stocks that are gaining faster than the overall market. Some of the best-performing stocks today ahead of markets opening are as below:

    Tiziana Life Sciences PLC [TLSA]

    Tiziana Life Sciences PLC is a top gainer this morning and is up by over 10% and gaining. This follows the company’s announcement that following a strategic review, it was demerging its StemPrintER and SPARE genomics business into a different listed company, called Accustem. The company stated the move would allow Accustem to commercialize the StemPrintER technology with cash of about a million pounds. It’s a move that unlocks value for the company’s shareholders.

    Eastman Kodak [NYSE: KODK]

    Eastman Kodak is another top gainer this morning and is up by over 50%. This follows the company’s announcement that it was actively addressing allegations that it had mishandled the stock option grants for its CEO just before it announced the loan awarded by the U.S government. The company has stated that it had agreed to act on a report on this process, and that includes a reorganization of the board.

    Myomo Inc [NYSE: MYO]

    Myomo Inc is a top performer this morning and is up by over 40%. This follows the company’s announcement that it had been certified as a Medicare provider. This will enable the company to bill Medicare directly when delivering its services in Washington DC, and in 39 States.